Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
data
2
×
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
amgen
biotech
boston blog main
boston top stories
cholesterol
clinical study
clinical trials
disease
enzyme
gag
gene editing
genome editing
hunter syndrome
ids
inclisiran
ldl
mark timney
mps ii
mt sinai hospital
mucopolysaccharidosis ii
new york
new york blog main
new york top stories
pcsk9
peter wijngaard
praluent
prashant vaishnava
regeneron pharmaceuticals
repatha
san francisco
sandy macrae
sangamo therapeutics
sanofi
studies
What
medicine
nasdaq
2
×
aces
announced
benefit
big
ceo
cholesterol
drug
editing
flexible
gene
going
humans
inclisiran
isn't
key
landmark
little
lowering
meant
medco
medicines
morning
open
passed
phase
pricing
reported
reports
results
sangamo
study
taken
test
therapeutics
trial
twice
u.s
week
Language
unset
Current search:
nasdaq
×
data
×
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
5 years ago
In Landmark Gene-Editing Study, Sangamo Reports Little Benefit
